ClinicalTrials.gg
CompletedNCT01456169Updated Apr 23, 2014Results posted

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

A Phase 3 interventional study of Azilsartan medoxomil/placebo and Azilsartan medoxomil - chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 108 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Essential Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Takeda.

Enrollment
11th of 15
507 · median 669
Started
2011
the only one that year
Phase 3
12 of 15
none open now
Registered
11th of 15
by date

Among the 15 studies in Essential Hypertension by Takeda, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 12 in phase 3, and was the 11th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 15 studies in Essential Hypertension by Takeda is open now. The open studies under Essential Hypertension, anywhere →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Essential Hypertension by Takeda as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.

Read the detailed description

Eligible participants completed a 2-week single-blind run-in period (Days -42 to -29) prior to a Single-Blind Monotherapy Treatment Period (Day -28 to Day -1) where they received azilsartan medoxomil 40 mg. After the Single-Blind Monotherapy Treatment Period, those participants who achieved target blood pressure discontinued treatment and resumed standard of care management at the discretion of their treating physician, while those participants who did not achieve target blood pressure (defined as clinic systolic blood pressure ≥140 mmHg) were randomly assigned to 1 of 3 active treatment arms: azilsartan medoxomil 40 mg plus placebo, azilsartan medoxomil plus chlorthalidone 40/12.5 mg, or azilsartan medoxomil plus chlorthalidone 40/25 mg.

03

Conditions studied

  • Essential Hypertension

Keywords

  • High Blood Pressure
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At Screening

  1. The participant has grade 2-3 essential hypertension which is not adequately controlled, as defined by mean, trough, sitting, clinic systolic blood pressure (SBP):

    • ≥160 to ≤180 mm Hg in participants who have not received any antihypertensive medication in the 14 days prior to Visit 1.
    • ≥150 to ≤170 mm Hg in participants taking 1 antihypertensive medication at Visit 1.
    • ≥140 to ≤160 mm Hg in participants taking 2 antihypertensive medications at Visit 1.
  2. The participant has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the investigator does not consider the results to be for precluding entry in to the study in this hypertensive population.
  3. The participant is willing to discontinue current antihypertensive medications.
  4. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  5. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  6. Male or female adult, at least 18 years of age.
  7. A female of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of the informed consent through 30 days after the last study drug dose. NOTE: Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [performed more than one 1 year prior to Screening]) or who are (defined as at least 1 year since last regular menses).

    Post-placebo run-in:

  8. The participant must have a post-placebo run-in, 24-hour mean SBP by ambulatory blood pressure monitoring (ABPM) of 140-175 mm Hg inclusive, and a clinic SBP measurement of 160 to 190 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -29) to qualify for entry in to the 4 week single-blind TAK-491 40 mg monotherapy treatment period.

    Post-4 week, single-blind TAK-491 40 mg monotherapy treatment:

  9. The participant does not achieve target blood pressure (defined as clinic SBP ≥140 mm Hg as determined by the mean of 3 sitting, trough, measurements) following 4 weeks single-blind treatment with TAK-491 40 mg monotherapy at Day -1, prior to randomization to double-blind treatment.

Exclusion criteria

Exclusion Criteria:

At Screening

  1. The participant has clinic diastolic blood pressure (DBP) >110 mm Hg.
  2. The participant's 3 SBP measurements differ by more than 15 mm Hg (confirmed by a second set of three measurements).
  3. The participant has received any compound within 30 days prior to Screening or is currently participating in another investigational study. NOTE: Participants participating in observational studies (per local definition) may enter Screening provided that the last intervention or invasive procedure was >30 days prior to Visit 1.
  4. The participant has been randomized/enrolled in a previous TAK-491 or TAK-491CLD study. NOTE: This criterion does not apply to participants who entered screening or placebo run-in in another TAK-491 or TAK-491CLD study but were not randomized/enrolled.
  5. The participant is a study site employee or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant is currently treated with more than 2 antihypertensive medications.
  7. The participant works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).
  8. The participant has an upper arm circumference \<24 cm or >42 cm.
  9. The participant has secondary hypertension of any etiology (e.g., renovascular disease, pheochromocytoma, Cushing's syndrome).
  10. The participant has any history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, persistent or permanent atrial fibrillation or .
  11. The participant has cardiac conduction defects (e.g., third-degree atrioventricular block, sick sinus syndrome).
  12. The participant has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease or hypertrophic cardiomyopathy.
  13. The participant has severe renal dysfunction or disease [based on estimated (eGFR) \<30 mL/min/1.73m\^2 at screening], prior renal transplantation or nephrotic syndrome (defined as a urinary albumin/creatinine ratio >2000 mg/g at Screening).
  14. Participant has known hemodynamically significant bilateral renal artery stenosis or unilateral disease in a single kidney.
  15. The participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of single-blind TAK-491 monotherapy study drug. (This criterion does not apply to those participants with basal cell or Stage 1 squamous cell carcinoma of the skin).
  16. The participant has poorly-controlled type 1 or 2 diabetes mellitus ( [HbA1c] >8.5%) at Screening.
  17. The participant has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal reference range of the central laboratory) at Screening.
  18. The participant has an or aspartate aminotransferase level >2.5 times the , active liver disease, or jaundice at Screening.
  19. The participant has any other known serious disease or condition that would compromise safety, might affect , or make it difficult to successfully manage and follow the participant according to the protocol.
  20. The participant has a history of or allergies to angiotensin II receptor blockers (ARB) or thiazide-type diuretics or other sulfonamide-derived compounds.
  21. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse per local guidelines within the past 2 years.
  22. The participant is required to take excluded medications at any point during the study.
  23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.

    Post-placebo run-in period

  24. The participant has a clinic SBP >190 mm Hg and DBP >115 mm Hg.
  25. The participant is noncompliant (\<70% or >130%) with study medication during the placebo run-in period.
  26. The participant has a 24-hour mean eligibility ABPM reading of insufficient quality.

    Post-single-blind TAK-491 40 mg treatment period

  27. The participant has a clinic SBP >180 mm Hg and DBP >110 mm Hg.
  28. The participant is noncompliant (\<70% or >130%) with study medication during the TAK-491 40 mg single-blind treatment period.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
507 participants (actual)

Study arms

  • Active comparator
    Azilsartan medoxomil 40 mg

    Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.

    Drug: Azilsartan medoxomil/placebo

  • Experimental
    Azilsartan medoxomil + chlorthalidone 40/12.5 mg

    Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.

    Drug: Azilsartan medoxomil - chlorthalidone

  • Experimental
    Azilsartan medoxomil + chlorthalidone 40/25 mg

    Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.

    Drug: Azilsartan medoxomil - chlorthalidone

Interventions

  • DrugAzilsartan medoxomil/placebo

    Azilsartan medoxomil and placebo to chlorthalidone combination tablets

    Also known as: TAK-491, EDARBI

  • DrugAzilsartan medoxomil - chlorthalidone

    Azilsartan medoxomil and chlorthalidone fixed dose combination tablets

    Also known as: TAK-491CLD, Edarbyclor

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

    The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline (of the double-blind treatment period) and Week 8

Secondary outcomes

  1. Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

    The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 8

  2. Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

    The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8, 22-24 hours after dosing

  3. Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

    The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8, 22-24 hours after dosing

  4. Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8

  5. Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8

  6. Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8

  7. Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8

  8. Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8

  9. Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8.

  10. Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8

  11. Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8

  12. Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8

    Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements.

    Time frame: Week 8

  13. Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8

    Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Week 8

  14. Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8

    Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure.

    Time frame: Week 8

07

Results

Posted Apr 23, 2014

Participant flow

A total of 1754 patients were screened at 125 investigative sites in Bulgaria, Estonia, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Serbia, Slovakia, Spain, Sweden, and the United Kingdom from 31 October 2011 to 24 January 2013.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Started133127135
Completed123122123
Not completed10512
Withdrew: Adverse event127
Withdrew: Major protocol deviation323
Withdrew: Voluntary withdrawal302
Withdrew: Lack of efficacy200
Withdrew: Other110

Outcome measures

PrimaryChange From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline (of the double-blind treatment period) and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline150.7 ± 0.96149.8 ± 0.98149.8 ± 0.95
Change from Baseline to Week 8-6.4 ± 1.05-15.8 ± 1.08-21.1 ± 1.04
Statistical analysis
  • Azilsartan Medoxomil 40 mg vs Azilsartan Medoxomil + Chlorthalidone 40/25 mg · ANCOVA · p = <0.001 · Ls mean difference: -14.7 · 95% CI -17.6 to -11.8ANCOVA model with treatment as a fixed effect and baseline trough, sitting, clinic SBP as a covariate.
  • Azilsartan Medoxomil 40 mg vs Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg · ANCOVA · p = <0.001 · Ls mean difference: -9.5 · 95% CI -12.4 to -6.5ANCOVA model with treatment as a fixed effect and baseline trough, sitting, clinic SBP as a covariate
SecondaryChange From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline89.8 ± 0.7387.7 ± 0.7588.8 ± 0.72
Change from Baseline to Week 8-3.2 ± 0.65-7.7 ± 0.67-10.3 ± 0.65
SecondaryChange From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8, 22-24 hours after dosing
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline143.1 ± 1.55140.2 ± 1.62142.0 ± 1.58
Change from Baseline to Week 8-2.5 ± 1.31-14.0 ± 1.36-16.6 ± 1.32
SecondaryChange From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8, 22-24 hours after dosing
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline86.4 ± 1.1183.6 ± 1.1686.0 ± 1.12
Change from Baseline to Week 8-2.2 ± 0.88-8.8 ± 0.92-9.4 ± 0.89
SecondaryChange From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline138.0 ± 1.21137.0 ± 1.26138.2 ± 1.22
Change from Baseline to Week 8-2.3 ± 1.02-14.7 ± 1.07-18.1 ± 1.03
SecondaryChange From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline81.9 ± 0.8980.3 ± 0.9382.5 ± 0.91
Change from Baseline to Week 8-1.6 ± 0.66-8.5 ± 0.69-10.1 ± 0.67
SecondaryChange From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline141.5 ± 1.24141.1 ± 1.30141.9 ± 1.26
Change from Baseline to Week 8-2.4 ± 1.09-15.3 ± 1.14-18.2 ± 1.11
SecondaryChange From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline84.9 ± 0.9683.6 ± 1.0185.7 ± 0.98
Change from Baseline to Week 8-1.7 ± 0.72-8.9 ± 0.75-10.1 ± 0.73
SecondaryChange From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline127.3 ± 1.50124.2 ± 1.57126.3 ± 1.52
Change from Baseline to Week 8-2.2 ± 1.18-12.7 ± 1.24-17.3 ± 1.20
SecondaryChange From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline73.2 ± 0.9570.6 ± 0.9972.9 ± 0.97
Change from Baseline to Week 8-1.6 ± 0.78-7.2 ± 0.82-9.8 ± 0.79
SecondaryChange From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline141.6 ± 1.30141.8 ± 1.36142.3 ± 1.32
Change from Baseline to Week 8-2.3 ± 1.14-15.4 ± 1.19-18.2 ± 1.16
SecondaryChange From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
mm HgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Baseline85.2 ± 1.0184.2 ± 1.0586.0 ± 1.02
Week 8-1.6 ± 0.75-8.9 ± 0.78-10.1 ± 0.76
SecondaryPercentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8

Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8
percentage of participantsAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 835.362.777.8
SecondaryPercentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8

Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8
percentage of participantsAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 860.281.085.9
SecondaryPercentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8

Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8
percentage of participantsAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 830.859.574.1

Adverse events

Collected over For 4 weeks during the monotherapy treatment period and from the first dose of double-blind study drug up to 14 days (or 30 days for a Serious AE) after the last dose of study drug in the 8-week double-blind treatment period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy: Azilsartan Medoxomil 40 mg—3/507 (0.6%)15/507 (3%)
Azilsartan Medoxomil 40 mg—2/133 (1.5%)15/133 (11.3%)
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg—0/127 (0%)13/127 (10.2%)
Azilsartan Medoxomil + Chlorthalidone 40/25 mg—0/135 (0%)26/135 (19.3%)
Most frequent serious events
Most frequent serious events
EventMonotherapy: Azilsartan Medoxomil 40 mgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Myocardial infarctionCardiac disorders0/5071/1330/1270/135
Cerebrovascular accidentNervous system disorders1/5071/1330/1270/135
Acute myocardial infarctionCardiac disorders1/5070/1330/1270/135
Ventricular tachycardiaCardiac disorders1/5070/1330/1270/135
Blood pressure increasedInvestigations1/5070/1330/1270/135
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5070/1330/1270/135
Most frequent other events
Most frequent other events
EventMonotherapy: Azilsartan Medoxomil 40 mgAzilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mg
Blood creatinine increasedInvestigations2/5074/1334/12711/135
DizzinessNervous system disorders3/5070/1332/1276/135
HeadacheNervous system disorders9/5072/1333/1275/135
NasopharyngitisInfections and infestations6/5074/1332/1274/135
Viral infectionInfections and infestations0/5074/1330/1270/135
HypotensionVascular disorders0/5071/1332/1274/135

Baseline characteristics

Participants who were randomized into the double-blind treatment period. Baseline was defined as the last observed value while on monotherapy study drug and before the first dose of double-blind study drug.

Age, Continuous
Age, Continuous(years)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Mean57.9 ± 10.1859.2 ± 10.7257.7 ± 10.4658.2 ± 10.45
Age, Customized
Age, Customized(participants)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
< 45 years13101235
45 to < 65 years877988254
≥ 65 years333835106
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Female465444144
Male877391251
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
American Indian or Alaska Native1012
Asian0101
Black or African American1001
Native Hawaiian or Other Pacific Islander0011
White132126134392
Multiracial1012
Region of Enrollment
Region of Enrollment(participants)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Bulgaria11101132
Estonia18161852
France2125
Germany29292886
Hungary1091029
Italy64515
Lithuania54615
Netherlands46515
Poland17181752
Serbia43411
Slovakia24242674
Spain1113
Sweden1214
United Kingdom1012
Weight
Weight(kg)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Mean87.59 ± 15.79486.71 ± 17.03787.39 ± 14.87687.24 ± 15.868
Height
Height(cm)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Mean171.8 ± 8.87170.6 ± 9.96172.1 ± 9.74171.5 ± 9.53
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Azilsartan Medoxomil 40 mgAzilsartan Medoxomil + Chlorthalidone 40/12.5 mgAzilsartan Medoxomil + Chlorthalidone 40/25 mgTotal
Mean29.63 ± 5.06629.78 ± 5.20629.52 ± 4.57229.64 ± 4.937

8 further baseline measures are reported on the registry.

08

Study locations

108 sites
  • Haskovo, Bulgaria
  • Pazardzhik, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Paide, Estonia
  • Saku, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Voru, Estonia
  • Labarthe Sur Leze, Haute Garonne, France
  • Bourg-des-Comptes, Ille et Vilaine, France
  • Tours, Indre et Loire, France
  • Vourey, Isere, France
  • Saint Etienne, Loire, France
  • Orthez, Pyrenees Atlantiques, France
  • Karlsruhe, Baden Wuerttemberg, Germany
  • Bad Woerishofen, Bayern, Germany
  • Nuernberg, Bayern, Germany
  • Frankfurt, Hessen, Germany
  • Stuhr, Niedersachsen, Germany
  • Essen, Nordrhein Westfalen, Germany
  • Kamp-Lintfort, Nordrhein Westfalen, Germany
  • Mainz, Rheinland Pfalz, Germany
  • Dresden, Sachsen, Germany
  • Hamburg, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyongyos, Hungary
  • Gyula, Hungary
  • Mosonmagyarovar, Hungary
  • Nyiregyhaza, Hungary
  • Pecs, Hungary
  • Szikszo, Hungary
  • Torrette di Ancona, Ancona, Italy
  • Acquaviva delle Fonti, Bari, Italy
  • Legnago, Verona, Italy
  • Bologna, Italy
  • Brescia, Italy
  • Ferrara, Italy
  • L'Aquila, Italy
  • Milano, Italy
  • Palermo, Italy
  • Pavia, Italy
  • Pisa, Italy
  • Roma, Italy
  • Sassari, Italy
  • Alytus, Lithuania
  • Kaunas, Lithuania
  • Beek, Netherlands
  • Breda, Netherlands
  • Eindhoven, Netherlands
  • Groningen, Netherlands
  • Leiderdorp, Netherlands
  • Maastricht, Netherlands
  • Rotterdam, Netherlands
  • Velp, Netherlands
  • Zoetermeer, Netherlands
  • Zwijndrecht, Netherlands
  • Bydgoszcz, Poland
  • Gdansk, Poland
  • Gdynia, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Oswiecim, Poland
  • Parczew, Poland
  • Poznan, Poland
  • Pulway, Poland
  • Rzeszow, Poland
  • Sopot, Poland
  • Torun, Poland
  • Zgierz, Poland
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Krusevac, Serbia
  • Nis, Serbia
  • Sremska Kamenica, Serbia
  • Zemun, Serbia
  • Bardejov, Slovakia
  • Bratislava, Slovakia
  • Galanta, Slovakia
  • Komarno, Slovakia
  • Kosice, Slovakia
  • Lucenec, Slovakia
  • Martin, Slovakia
  • Nitra, Slovakia
  • Nove Zamky, Slovakia
  • Presov, Slovakia
  • Svidnik, Slovakia
  • Zilina, Slovakia
  • Centelles, Barcelona, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Malaga, Spain
  • Goteborg, Sweden
  • Lund, Sweden
  • Malmo, Sweden

Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Dec 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2011
First posted
Oct 20, 2011
Start
Oct 2011
Primary completionActual
Dec 2012
CompletionActual
Jan 2013
Results first posted
Apr 23, 2014
Last update
Apr 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01456169
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 20, 2011
Start date
Oct 2011
Primary completion
Dec 2012
Completion
Jan 2013
Results posted
Apr 23, 2014
Last update
Apr 23, 2014

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion